{
    "nctId": "NCT02624908",
    "officialTitle": "Canagliflozin-Mealtime Insulin Rescue",
    "inclusionCriteria": "* use of basal-bolus insulin\n* onset of diabetes after age 30\n* BMI less than 35\n* eGFR at least 60 ml/mn\n* Hb A1c 7.0-10.0%\n* willingness to perform home glucose monitoring\n* willingness to transmit glucose and medication information weekly\n* Must have minimum age of 30 Years\n* Must have maximum age of 70 Years",
    "exclusionCriteria": "* Type 1 diabetes\n* Known peripheral artery disease\n* Liver enzymes equal or more than 1.5 times the upper limit of normal\n* Chronic heart failure NYHA class III or IV\n* Current haemodialysis or peritoneal dialysis\n* End stage liver disease, defined as acute or chronic liver disease and recent history of one of the following: ascites, encephalopathy, variceal bleeding, bilirubin equal or greater than 2.0 mg/dL, albumin equal or less than 3.5 g/ dL, prothrombin time greater or equal to 4 seconds, INR greater than or equal to 1.7 or prior liver transplant\n* Known or suspected hypersensitivity to trial products or related products\n* Female of child-bearing potential who is pregnant, breast-feeding or intends to become pregnant or is not using adequate contraceptive methods as required by law or local practice.\n* Expected simultaneous participation in any other clinical trial of an investigational medicinal product.\n* Receipt of any investigational medicinal product within 30 days before randomization\n* Current or past (within the last 5 years) malignant neoplasms (except basal cell and squamous cell skin carcinoma)\n* Any condition that in the investigator's opinion would make the subject unable to adhere to the trial visit schedule and procedures\n* Known history of non-compliance to treatment."
}